Coronavirus disease 2019 (COVID-19) is affecting millions of patients worldwide. 
It is caused by the severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2), which belongs to the family Coronaviridae, with 80% genomic 
similarities to SARS-CoV. Lymphopenia was commonly seen in infected patients and 
has a correlation to disease severity. Thrombocytopenia, coagulation 
abnormalities, and disseminated intravascular coagulation were observed in 
COVID-19 patients, especially those with critical illness and non-survivors. 
This pandemic has caused disruption in communities and hospital services, as 
well as straining blood product supply, affecting chemotherapy treatment and 
haematopoietic stem cell transplantation schedule. In this article, we review 
the haematological manifestations of the disease and its implication on the 
management of patients with haematological disorders.